Drug Price Transparency
The Centers for Medicare & Medicaid Services today issued a proposed rule aimed at increasing drug price transparency and reducing the price of prescription drugs and biological products to consumers by requiring drug manufacturers to include list prices in all direct-to-consumer television…
The House of Representatives yesterday passed two bills that would prohibit health plans from restricting a pharmacist’s ability to inform enrollees when a drug would cost less without using their insurance.
The Senate last night voted 98-2 to approve the Patient Right to Know Drug Prices Act (S. 2554), a bill that would prohibit private health plans from restricting a pharmacist’s ability to inform enrollees when a drug would cost less without using their insurance.
A coalition of health care providers, insurers, seniors and others is pushing back on some of the latest claims by the Pharmaceutical Research and Manufacturers of America that incorrectly blame hospitals for the rising price of drugs.
AHA letter to the US Senate supporting Amendment #3787 to address ‘out-of-control cost’ of prescription drugs.
AHA comments on the 340B section of the Department of Health and Human Services’ Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
AHA commends MedPAC and HHS for voicing significant concerns about rising pharmaceutical costs.
The American Hospital Association and others support Senators Grassley and Feinstein of the Senate Judiciary Committee for their leadership and commitment to reducing out-of-control prescription drug prices and stopping anti-competitive abuses that keep drug prices high.
Read the full letter below…
AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing Program ceiling price and drug manufacturers’ civil monetary penalties (CMPs) for violations of the ceiling price.